This profile is built from public research funding records (CIHR, NSERC and SSHRC). We have not imported them from a University of Calgary directory, so their publications, courses and email address may be missing. Find their university profile.
Research
Latest funding
- $1,300,500
Chronic Graft-versus-Host Disease Polyomic Profiling as Predictive Biomarker Patterns to Guide Therapy
CIHR · 2025 · Co-investigator
- $606,576
A pilot project to demonstrate feasibility of a Canadian gene therapy clinical trials platform for rare genetic diseases: Gene Therapy for CD3delta Severe Combined Immune Deficiency.
CIHR · 2022 · Principal investigator
- $23,000,000
Canadian Pediatric Cancer Consortium
CIHR · 2022 · Co-investigator
Chronic Graft-versus-Host Disease Polyomic Profiling as Predictive Biomarker Patterns to Guide Therapy
Principal investigators: Schultz, Kirk R
Keywords: Biomarkers; Chronic Graft-Versus-Host Disease; Hematopoietic Stem Cell Transplantation; Immune Tolerance; Metabolomics; Therapy
A pilot project to demonstrate feasibility of a Canadian gene therapy clinical trials platform for rare genetic diseases: Gene Therapy for CD3delta Severe Combined Immune Deficiency.
Principal investigators: Wright, Nicola A; Cuvelier, Geoff; Grunebaum, Eyal; Guilcher, Greg; Kohn, Donald B; Lewis, Victor; Marwaha, Ashish K; Murguia-Favela, Luis E; Narendran, Aru; Prokopishyn, Nicole L; Romero Garcia, Zulema; Suresh, Sneha
Keywords: Adenine Base Editing; Gene Editing; Gene Therapy Clinical Trial; Inborn Errors Of Immunity; Rare Diseases; Severe Combined Immune Deficiency
Canadian Pediatric Cancer Consortium
Principal investigators: David Malkin, James Whitlock; Co-Dyre, Adrienne; McIntosh, Keith A; Denburg, Avram E; Deyell, Rebecca J; Duval, Michel; Jabado, Nada; Marjerrison, Stacey L; Rayar, Meera; Tsimicalis, Argerie
Keywords: Cancer -Omics; Cancer Modeling; Clinical Trials; Community Engagement; Implementation Science; Innovative Therapies; Knowledge Mobilization; Pan-Canadian Consortium; Pediatric Cancer; Training And Mentorship
A pilot project to demonstrate feasibility of a Canadian gene therapy clinical trials platform for rare genetic diseases: Gene Therapy for CD3delta Severe Combined Immune Deficiency.
Principal investigators: Wright, Nicola A; Cuvelier, Geoff; Grunebaum, Eyal; Guilcher, Greg; Kohn, Donald B; Lewis, Victor; Marwaha, Ashish K; Murguia-Favela, Luis E; Narendran, Aru; Prokopishyn, Nicole L; Romero Garcia, Zulema; Suresh, Sneha
Keywords: Adenine Base Editing; Gene Editing; Gene Therapy Clinical Trial; Inborn Errors Of Immunity; Rare Diseases; Severe Combined Immune Deficiency
Applying Biomarkers to Long-term Effects in Child and Adolescent Cancer Treatment (ABLE Team)
Principal investigators: Schultz, Kirk R; Baruchel, Sylvain; Mcbride, Mary L; Mitchell, Lesley G; Rassekh, Shahrad R; Tsuyuki, Ross T; Zappitelli, Michael
Keywords: Biomarkers; Chronic Graft Versus Host Disease; Clinical Interventions; Long Term Effects Of Cancer Therapy; Nephrotoxicity; Oto-Toxicity; Thrombosis
Applying Biomarkers to Long-term Effects in Child and Adolescent Cancer Treatment (ABLE Team)
Principal investigators: Schultz, Kirk R; Baruchel, Sylvain; Blydt-Hansen, Tom; Brandao, Leonardo R; Broady, Raewyn; Cuvelier, Geoff; Lee, Agnes Yuet Ying; Mcbride, Mary L; Mitchell, Lesley G; Pinsk, Maury N; Rassekh, Shahrad R; Ross, Colin J; Spavor, Maria; Tsuyuki, Ross T; Zappitelli, Michael
Keywords: Biomarkers; Chronic Graft-Versus-Host Disease; Clinical Interventions; Long Term Effects Of Cancer Therapy; Nephrotoxicity; Oto-Toxicity; Thrombosis
From CIHR, NSERC and SSHRC funding decisions: CIHR since 2008, NSERC since 1991 and SSHRC since 1998, including their latest published competition results.
A short, specific email works best. This draft uses one of their recent papers; replace the parts in brackets with your own details before sending.